Currently, several disease-modifying therapies for the treatment of multiple sclerosis are
established and more are likely to be introduced. These treatment options differ with respect …

Current therapeutic landscape in multiple sclerosis: an evol... : Current Opinion in
Neurology Current therapeutic landscape in multiple sclerosis: an evolving treatment …

Multiple sclerosis, the most common neurologic disorder of young adults, is traditionally
considered to be an inflammatory, autoimmune, demyelinating disease of the central …

Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous
system (CNS). It predominantly affects young women and is one of the most common causes …

The modern treatment era for multiple sclerosis (MS) began in 1993 with the approval of the
first disease-modifying agent. Since then the field has greatly expanded, with 10 therapies …

Multiple sclerosis (MS) has been thought to be a complex and indecipherable disease, and
poorly understood with regards to aetiology. Here, we suggest an emphatically positive view …

Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the
central nervous system and the most common cause of neurological disability in young …

Multiple sclerosis (MS) is a presumed autoimmune disorder of the central nervous system,
resulting in inflammatory demyelination and axonal and neuronal injury. New diagnostic …

Although there has been unequivocal progress in the development of treatments for multiple
sclerosis over the last 20 years, currently licensed treatments have demonstrated convincing …

Several disease‐modifying drugs (DMDs) are currently approved for the treatment of
multiple sclerosis (MS). Recently, there has been increased identification and development …